This post is also available in: English Slovenščina (Slovenian)

Biological drugs mostly differ from classical agents in their molecular mass, complex three-dimensional structure, molecular heterogeneity and imunogenity. Moreover, the most important aspect of these agents is their capability of targeting specific signal molecules, consequently causing no or less damage to the non-targeted tissue. Hence, this fact led to widely accepted belief that biopharmaceutical drugs are among the safest on the market. During the conduct of different studies researchers found new physiological roles of targeted molecules that were previously unknown. These findings overruled the assumption about targeted therapy being selective and specific and made the researchers question their safety. Over the last two decades, there has been an exponential growth of investments into the development of new molecular therapies. Hence, there are a lot of studies underway and more targeted biologic drugs registered every year.